Core One Labs Inc. applauds the findings of a research study published in Military Psychology on February 01, 2023, that revealed the treatments of psychedelic substances substantially reduced alcohol misuse and Post Traumatic Stress Disorder (PTSD) symptoms amongst its participants, which were U.S. Special Operations Forces (SOF) veterans. The research analyzed data from 45 male SOF veterans undergoing a clinical treatment program using ibogaine, a hallucinogenic compound derived from the roots of a West African shrub, and 5-MeO-DMT, a psychedelic substance found in a number of plant species, that was carried out in Mexico. The partakers completed psychological assessments of alcohol use, posttraumatic stress disorder symptoms and cognitive symptoms prior to the treatment, and then 1 month, three months and six months after the treatment.

Participants that were screened comprised of 29% that were considered moderate-risk drinkers, 29% that were categorized as high-risk drinkers and 42% that were classified as severe-risk drinkers. The findings revealed that one month after treatment, there was a significant decrease in alcohol consumption with 24% of the participants being abstinent and 33% engaging in non-risk drinking. There still remained 42% that were considered still risky drinkers.

Respondents that refrained from alcohol consumption expressed a reduction in PTSD symptoms and improvements in cognitive functioning in their follow-up psychological assessments, one month after the treatment. According to the study's lead author Stacey B. Armstrong, a clinical psychologist and postdoctoral scholar at the Center for Psychedelic Drug Research and Education at The Ohio State University, suggested that the combined ibogaine and 5-MeO- DMT treatment is an effective and robust treatment to reduce problematic alcohol use, and further added that not only were these outcomes established relatively quickly, effects maintained through 6 months post-treatment.